Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the GBM vaccine VBI-1901 for safety, tolerability, and dose optimization in recurrent glioblastoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• VBI-1901

Snippet

Sponsor: VBI Vaccines Inc. | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: RECRUITING